The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.
White Paper
IND Ready Is Not Phase 2 Ready
Related Resources
All Resources
post
The FDA’s CNPV Pilot Is Reshaping Drug Development—Is Your Program Ready to Leverage It?
Read More
post
Ensuring Data Integrity in Pharma: Best Practices for Compliance
Read More
infographic
Common Hurdles Sponsors Face upon a Marketing Application Submission
Read More
post
Cloud and AI in Pharma: Driving Digital Transformation in Pharmaceutical Operations
Read More
Let's move from science to success.
Let’s Talk